Revenue segments as reported by the company.

Subscription services

Professional services and other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and admin

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veeva Systems

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Veeva Systems reports robust Q1 earnings, eyes growth opportunities

Veeva Systems delivered strong financial performance in Q1 2023, driven by robust execution and competitive wins. The company's focus on innovation, AI capabilities, and the transition to Vault CRM presents significant growth opportunities. However, challenges in the funding environment and customer migrations pose potential hurdles.

Veeva exceeds Q2 expectations, anticipates growth in clinical and data business

Veeva's Q2 performance exceeded expectations, leading to an increase in full-year guidance. The company's strengths lie in strong clinical activity, customer wins, and a focus on product excellence. However, challenges include migration costs, competitive landscape considerations, and marketing spend scrutiny. Veeva sees opportunities in M&A, minimal impact from R&D trends, and expansion of Veeva Link.

Veeva Systems surpasses Q3 expectations, eyes clinical data opportunity

Veeva Systems delivered a strong Q3 performance, with solid revenue and operating income. While facing challenges in billings and macroeconomic uncertainties, the company remains confident in its revenue target for fiscal year '25. The commitment from major enterprises and the potential in clinical data present significant opportunities for future growth.

Veeva Systems reports strong Q4 performance and forecasts $2.8B revenue

Veeva Systems showcases strong performance and strategic planning with revenue growth expectations of at least 15% in fiscal '24 and '25.
Positive feedback on product transitions and development, along with specialized sales teams, highlights market acceptance and innovation.
Challenges include short-term revenue impacts from timing-related issues and macro environment effects on customer spending.
Opportunities lie in revenue growth forecasts, product innovation, and market differentiation through new offerings and strategic deals.

Veeva Systems reports robust Q1 revenue growth and strategic focus

Veeva Systems' Q1 performance reflects strong revenue growth and a focus on customer-centric innovation. The company faces challenges in project scrutiny and competition but has opportunities in new product monetization and segment expansion.

Veeva Systems excels in Q2, eyes disciplined growth and innovation

Veeva Systems showcased robust financial performance, exceeding revenue and operating income targets, with a strong focus on customer success and product excellence.
While facing challenges such as migration costs and regulatory impacts, Veeva is well-positioned to leverage opportunities in disciplined M&A and product innovation.
The company's strategic growth initiatives, including Veeva Link expansion and CRM platform enhancements, aim to drive continued success and value for customers.

Veeva Systems posts solid Q3 results, eyes growth opportunities

Veeva Systems delivered a strong Q3 performance with solid revenue and operating income, showcasing financial stability and growth potential.
Despite challenges like trimmed billings and deal delays, Veeva remains confident in its fiscal year '25 revenue target, emphasizing strategic focus and operational efficiency.
The company's strengths in innovative products, strong partnerships, and global support ecosystem position it well for future growth and market leadership.
Opportunities in customer migration, AI integration, and market demand present avenues for Veeva to drive revenue growth and enhance its competitive positioning in the industry.

Veeva Systems excels in Q4 earnings, poised for strategic growth

Veeva Systems delivered strong financial performance in Q4 2024, showcasing revenue growth, operating income efficiency, and strategic product advancements.
The company's focus on innovation, customer success, and disciplined financial guidance positions it well for future growth and market leadership.
While facing challenges related to market uncertainties and operational considerations, Veeva remains resilient and poised to capitalize on opportunities for expansion and differentiation.
Overall, Veeva's Q4 earnings call highlights a balanced approach to growth, operational excellence, and strategic decision-making in a dynamic business environment.

Veeva Systems beats Q1 guidance, lowers full-year outlook amid challenges

Veeva Systems had a strong start to the year, exceeding Q1 guidance but lowering full-year revenue outlook due to macro challenges.
The company's performance in margin, client adoption, and innovation remains robust, with a focus on stability and predictability amidst industry challenges.
Challenges include AI disruption impacting plans, lower revenue guidance, and delays in funding benefits due to global conflicts and interest rate sensitivity.
Opportunities lie in new client bases, EDC deals progress, and the potential growth of Vault Basics and Link products in the market.

Veeva Systems excels in Q2, eyes strategic growth opportunities

Veeva Systems delivered a strong Q2 performance with revenue of $676 million and non-GAAP operating income of $280 million, driven by product expansions and customer wins.
The company's strengths lie in its comprehensive clinical suite, customer comfort with CRM solutions, and the importance of professional services for customer success.
Challenges include short-term billing growth constraints and the need for continuous product excellence, while opportunities exist in data architecture enhancement and upcoming Investor Day insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.

Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

New clinical data application harmonizes study data from multiple sources to provide complete and concurrent clinical trial data PLEASANTON, Calif. , Oct. 18, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of Veeva CDB, a first-of-its-kind solution for aggregating, cleaning, and transforming clinical data.

Veeva CDB Application to Streamline Aggregation, Cleaning, and Transformation of Clinical Data

Veeva ePRO simplifies the collection and exchange of patient-reported outcomes in digital clinical trials PLEASANTON, Calif. , Oct. 18, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of Veeva ePRO, a key advancement in patient-centric digital trials.

Veeva Introduces New ePRO Application for Faster Access to Patient Data

Leading CROs unifying trial data and processes for greater visibility and speed PLEASANTON, Calif. , Oct. 17, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 40 contract research organizations (CROs) selected Veeva Vault CTMS to deliver faster and more efficient trials to sponsors, which includes four of the top six global CROs.

40 CROs Select Veeva Vault CTMS to Drive Clinical Trial Operations

Veeva Link SiteBase and Veeva Link TrialBase identify sites and optimize trial design   PLEASANTON, Calif. , Oct. 13, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced two new Veeva Link applications to help clinical teams improve site selection and optimize trial design.

New Veeva Link Applications Give Clinical Teams Real-Time Intelligence to Optimize Site Selection and Trial Design

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

These stocks are trading down, but it would be a mistake to overlook them in the current market.

2 Smart Stocks to Invest $1,000 In Right Now

Fast-growing biotechs and 15 of the top 20 pharma companies are accelerating modernization to streamline regulatory submissions on a single, unified platform PLEASANTON, Calif. , Oct. 4, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 350 companies are transforming regulatory operations with Veeva Vault RIM Suite applications to speed execution and keep pace with evolving health authority requirements.

Veeva Vault RIM Driving Greater Speed and Compliance for More Than 350 Life Sciences Organizations

This life sciences cloud company's results are resistant to a sputtering economy but not immune.

Will Veeva Systems Stock Rebound From Its Recent Sharp Downturn?

Datadog

PayPal

These stocks can help investors weather this difficult economic period.

3 Safe Tech Stocks You'll Regret Not Buying on the Dip

Veeva Systems' (VEEV) new offerings are expected to aid the marketing and field teams with more accurate and actionable insights into patient and HCP touchpoints.

Veeva Systems' (VEEV) Latest Launches to Enhance Workflow

PLEASANTON, Calif. , Sept. 29, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its financial analyst and investor day virtually on Thursday, November 3, 2022.

Veeva to Host Virtual Financial Analyst and Investor Day on Nov. 3, 2022

Veeva stock crushed the S&P 500 for a long while but trails this year. Will its brand-new business segment turn things around?

Where Will Veeva Systems Be in 10 Years?

Veeva Crossix HCP Trigger Data delivers patient engagement data for field and marketing teams to prioritize outreach to specific healthcare professionals Veeva Crossix Omnichannel Boost connects direct-to-consumer, healthcare professional, and field campaigns for deeper insights to optimize marketing performance PLEASANTON, Calif. , Sept. 28, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced two new Veeva Crossix solutions to help life sciences companies execute and optimize omnichannel marketing campaigns.

Veeva Crossix Introduces New Products to Advance Omnichannel Marketing for Life Sciences Brands

MercadoLibre

These stocks could handsomely reward investors given enough time.

2 Beaten-Down Cathie Wood Growth Stocks to Buy and Hold For 10 Years

Airbnb

Pubmatic

Some great businesses are trading at sale prices, so don't let fear keep you out of the market.

Have $5,000? These 3 Stocks Could Be Bargain Buys for 2022 and Beyond

Why Veeva Systems Stock Slid Today

The battle between the bulls and the bears has caused big swings in the stock over the last couple of years. Which side will win in the long run?

Veeva Systems Stock: Bear vs. Bull

Global CDMO boosts GxP compliance and inspection readiness with Veeva quality applications PLEASANTON, Calif. , Sept. 15, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Batavia Biosciences selected Veeva Vault Quality Suite to optimize its global quality assurance (QA), unifying content, processes, and training management on a single platform.

Batavia Biosciences Optimizes Global Quality Assurance with Veeva Vault Quality Suite

Is this beaten-down SaaS stock a value play or a value trap?

Veeva Systems Stock: Bull vs. Bear

DexCom

Teladoc

These growth-dependent healthcare stocks are sinking on the latest inflation update by the Labor Department.

Why DexCom, Teladoc Health, and Veeva Systems Shares Are Slumping Today

Keynote speakers AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK headline one of the industry's largest events for driving collaboration and innovation PLEASANTON, Calif. , Sept. 13, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that visionaries from AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK will be keynote speakers at the 2022 Veeva R&D and Quality Summit on Oct.19 and 20 in Boston.

More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development

Despite Veeva's short-term headwinds, this stock still looks pleasing for long-term investors.

3 Reasons I'm Still Bullish on Veeva Systems Stock

Leading companies share digital strategies and best practices for accelerating time to market PLEASANTON, Calif. , Sept. 8, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced its 2022 Veeva Industries Virtual Summit on Oct. 24-27, featuring leaders from the world's top consumer goods and chemical companies, including Unilever, Reckitt, Estée Lauder, Nestlé, BASF, and Evonik.

News for Veeva Systems Stock (VEEV)